Zarubaev V V, Garshinina A V, Kalinina N A, Shtro A A, Nebol'sin V E, Kiselev O I
Antibiot Khimioter. 2010;55(3-4):8-11.
The protective activity of Ingavirin against experimental infection caused by influenza B virus was studied on albino mice vs. Arbidol. Oral use of Ingavirin was shown to decrease the infectious titers of the virus in the animal lung tissue, to normalize the body weight dynamics, to lower the mortality and to increase the average lifespan vs. the placebo-treated animals. The activity of Ingavirin was higher than that of the reference drug. The results allowed to consider Ingavirin as a prospective agent for the treatment of influenza infection in humans.
在白化病小鼠身上研究了因加维林（Ingavirin）相对于阿比朵尔（Arbidol）对乙型流感病毒引起的实验性感染的保护活性。结果表明，与接受安慰剂治疗的动物相比，口服因加维林可降低动物肺组织中病毒的感染滴度，使体重动态恢复正常，降低死亡率并延长平均寿命。因加维林的活性高于参比药物。这些结果使人们可以将因加维林视为治疗人类流感感染的一种有前景的药物。
